Pyrimidine carboxamides as GSK-3 inhibitors

Patent metadata

Field	Value
Publication number	US-11053258-B2
Application number	US-201716463603-A
Country	US
Kind code	B2
Filing date	Nov 27, 2017
Priority date	Nov 28, 2016
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

First claim

We claim:

1. A compound of formula I

where:
R 1 is hydrogen, halo, alkyl, haloalkyl, alkoxy or haloalkoxy;
X is alkylene or alkenylene with 0-4 substituents selected from halo, alkyl, haloalkyl, hydroxy,
alkoxy, haloalkoxy, and (C 3-7 )-spirocycloalkyl; and
Y is O, piperazinyl, or morpholinyl;
or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 where Y is O.

3. A compound of claim 1 where Y is piperazinyl.

4. A compound of claim 1 where Y is morpholinyl.

5. A compound of claim 1 where X is (C 5-7 )-alkylene.

6. A compound of claim 1 where X is (C 5-6 )-alkenylene.

7. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. A method for the treatment of a condition selected from the group consisting of Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, argyophilic grain disease, corticobasal degeneration, Pick's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, Huntington's disease, and vascular dementia, which comprises administering to a patient in need thereof a therapeutically affective amount of a compound of claim 1 .

9. The method of claim 8 directed to the treatment of Alzheimer's disease.

Assignees

• Bristol Myers Squibb Co

Inventors

• Luo Guanglin
• Sivaprakasam Prasanna
• Dubowchik Gene M
• Macor John E

Classifications

• C07D498/22

  in which the condensed system contains four or more hetero rings · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title